MA30156B1 - IMMUNOGLOBULIN - Google Patents
IMMUNOGLOBULINInfo
- Publication number
- MA30156B1 MA30156B1 MA31108A MA31108A MA30156B1 MA 30156 B1 MA30156 B1 MA 30156B1 MA 31108 A MA31108 A MA 31108A MA 31108 A MA31108 A MA 31108A MA 30156 B1 MA30156 B1 MA 30156B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- hil
- diseases
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des immunoglobulines, en particulier des anticorps qui se lient spécifiquement à l'interleukine 13 humaine (hIL-13). Les anticorps de l'invention peuvent être utilisés dans le traitement de diverses maladies ou troubles qui réagissent à la modulation de l'interaction entre la hIL-13 et le récepteur de l'IL-13 humaine. Ces maladies comprennent l'asthme grave, la dermatite atopique, la BPCO ainsi que diverses maladies fibrotiques. La présente invention concerne également des compositions pharmaceutiques comprenant lesdits anticorps, ainsi que des procédés de fabrication.The present invention relates to immunoglobulins, particularly antibodies that bind specifically to human interleukin 13 (hIL-13). The antibodies of the invention can be used in the treatment of various diseases or disorders that respond to the modulation of the interaction between hIL-13 and the human IL-13 receptor. These diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. The present invention also relates to pharmaceutical compositions comprising said antibodies, as well as methods of manufacture.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30156B1 true MA30156B1 (en) | 2009-01-02 |
Family
ID=35997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31108A MA30156B1 (en) | 2006-01-11 | 2008-07-11 | IMMUNOGLOBULIN |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1976881A2 (en) |
JP (1) | JP2009523154A (en) |
KR (1) | KR20080113201A (en) |
CN (1) | CN101370829A (en) |
AR (1) | AR058955A1 (en) |
AU (1) | AU2007204372A1 (en) |
BR (1) | BRPI0706481A2 (en) |
CA (1) | CA2635972A1 (en) |
CR (1) | CR10161A (en) |
EA (1) | EA200801520A1 (en) |
GB (1) | GB0600488D0 (en) |
IL (1) | IL192207A0 (en) |
MA (1) | MA30156B1 (en) |
NO (1) | NO20082767L (en) |
PE (1) | PE20081185A1 (en) |
TW (1) | TW200736274A (en) |
WO (1) | WO2007080174A2 (en) |
ZA (1) | ZA200805526B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
MY157173A (en) | 2006-05-25 | 2016-05-13 | Glaxo Group Ltd | Modified humanised anti-interleukin-18 |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US20110236380A1 (en) * | 2008-11-26 | 2011-09-29 | De Wildt Rudolf M T | Ligands that bind il-13 |
NZ611324A (en) * | 2009-03-05 | 2015-02-27 | Abbvie Inc | Il-17 binding proteins |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
JP5919188B2 (en) * | 2009-05-28 | 2016-05-18 | グラクソ グループ リミテッドGlaxo Group Limited | IL-13 binding protein |
WO2011050071A2 (en) * | 2009-10-20 | 2011-04-28 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
ES2645368T3 (en) * | 2010-10-15 | 2017-12-05 | Medimmune Limited | Therapies to improve lung function |
CN112168962A (en) | 2010-12-16 | 2021-01-05 | 弗·哈夫曼-拉罗切有限公司 | Diagnosis and treatment associated with TH2 inhibition |
EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
KR20160068802A (en) | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | Methods of diagnosing and treating eosinophilic disorders |
UA117608C2 (en) | 2014-02-21 | 2018-08-27 | Дженентек, Інк. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
AU2015246037B2 (en) | 2014-04-11 | 2018-04-12 | Novartis Ag | Methods of selectively treating asthma using IL-13 antagonists |
CN107430117A (en) | 2015-03-16 | 2017-12-01 | 豪夫迈·罗氏有限公司 | Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases |
WO2017162604A1 (en) | 2016-03-21 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treatment of solar lentigo |
CN110198956A (en) * | 2017-01-23 | 2019-09-03 | 学校法人东洋大学 | Anti-EPHA 2 antibody and the EPHA2 immune detection for using the anti-EPHA 2 antibody |
CN109776677B (en) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | Humanized anti-IL-13 antibody and preparation method and application thereof |
CN107909501B (en) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | Smell and behavior association method, smell social method and device |
KR20220098056A (en) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
CA3133633A1 (en) * | 2019-03-20 | 2020-09-24 | Javelin Oncology, Inc. | Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003260748A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
HUE049161T2 (en) * | 2003-12-23 | 2020-09-28 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/en unknown
- 2007-01-09 AR ARP070100082A patent/AR058955A1/en unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/en not_active Application Discontinuation
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/en not_active Application Discontinuation
- 2007-01-10 EA EA200801520A patent/EA200801520A1/en unknown
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en active Application Filing
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/en not_active IP Right Cessation
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/en active Pending
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/en active Pending
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
-
2008
- 2008-06-16 NO NO20082767A patent/NO20082767L/en not_active Application Discontinuation
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/en unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/en unknown
- 2008-07-17 CR CR10161A patent/CR10161A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0706481A2 (en) | 2011-03-29 |
WO2007080174A3 (en) | 2007-12-06 |
JP2009523154A (en) | 2009-06-18 |
EP1976881A2 (en) | 2008-10-08 |
AR058955A1 (en) | 2008-03-05 |
EA200801520A1 (en) | 2009-02-27 |
WO2007080174A2 (en) | 2007-07-19 |
CR10161A (en) | 2008-11-26 |
AU2007204372A1 (en) | 2007-07-19 |
TW200736274A (en) | 2007-10-01 |
PE20081185A1 (en) | 2008-10-07 |
NO20082767L (en) | 2008-10-06 |
ZA200805526B (en) | 2009-10-28 |
GB0600488D0 (en) | 2006-02-22 |
CN101370829A (en) | 2009-02-18 |
KR20080113201A (en) | 2008-12-29 |
IL192207A0 (en) | 2008-12-29 |
CA2635972A1 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30156B1 (en) | IMMUNOGLOBULIN | |
BRPI0512826A (en) | chimeric and humanized monoclonal antibodies to interleukin-13 | |
MA30041B1 (en) | IMMUNOGLOBULIN | |
WO2003016466A3 (en) | ANTI-Aβ ANTIBODIES | |
MA35035B1 (en) | POLYPEPTIDE ANTIBODIES THAT ANTAGONIZE CD40 | |
MA32804B1 (en) | ISONICOTINAMIDE ANTAGONISTS OF OREXIN RECEPTORS | |
MA30462B1 (en) | ANTAGONIST PYRIDYLAMIDE COMPOUNDS OF T-TYPE CALCIUM CHANNELS | |
WO2002086443A8 (en) | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer | |
MA33402B1 (en) | COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES | |
TN2010000059A1 (en) | HUMAN ANTIBODIES WITH AFFINITY EXPRESSED FOR HUMAN NERVOUS GROWTH FACTOR | |
MA31016B1 (en) | DIAZEPAN COMPOUNDS SUBSTITUTED AS ANTAGONISTS OF OREXIN RECEPTORS. | |
MA27952A1 (en) | HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE INHIBITORS OF NGF PATHWAY | |
TNSN04078A1 (en) | ANTIBODIES TO CD40 | |
EP2325209A3 (en) | Improved protofibril selective antibodies and the use thereof | |
MA31899B1 (en) | Monoclonal antibodies are associated with hgm-csf and the medical structures they contain | |
MA30876B1 (en) | ANTIBODIES OF LYMPHOTOXIN-ALPHA | |
MA28289A1 (en) | IMMUNOGLOBULIN | |
TR200202254T2 (en) | Recombinant IL-18 antagonists useful in the treatment of IL-18 induced disorders. | |
MA31862B1 (en) | Antiseptic antibodies and their uses | |
DE60232660D1 (en) | HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS | |
MA27794A1 (en) | SUBSTITUTED DIHYDROQUINAZOLINES WITH ANTIVIRAL PROPERTIES | |
TNSN07398A1 (en) | ANTIBODIES AGAINST P-CADHERINE | |
MA29723B1 (en) | COMPOUNDS | |
MA30539B1 (en) | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES INDUCED BY THE GPR38 RECEPTOR. | |
MA33753B1 (en) | New Ariel Mycophenolate, methods of preparation and uses |